Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes

Journal of Investigative Medicine

Volumn 63, Issue 2, 2015, Pages 267-272

  Xu, Weijie ^a   Yang, Yan ^a   Yuan, Gang ^a   Zhu, Wenjun ^a   Ma, Delin ^a   Hu, Shuhong ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Alzheimer disease; Glucagon like peptide 1 receptor agonist; Insulin signaling pathway; Tau protein; Type 2 diabetes

Indexed keywords

EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN; PHOSPHATIDYLINOSITOL KINASE; PROTEIN KINASE B; SODIUM CHLORIDE; STREPTOZOCIN; TAU PROTEIN; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCOSE BLOOD LEVEL; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PEPTIDE; VENOM;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; GLUCOSE BLOOD LEVEL; HIPPOCAMPUS; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; AGONISTS; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

RATTUS;

ALZHEIMER DISEASE; ANIMALS; BLOOD GLUCOSE; BLOTTING, WESTERN; DIABETES MELLITUS, TYPE 2; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; HYPERGLYCEMIA; INSULIN; INSULIN RESISTANCE; MALE; PEPTIDES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; SIGNAL TRANSDUCTION; TAU PROTEINS; VENOMS;

EID: 84929302567     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.1097/JIM.0000000000000129     Document Type: Article

References (44)

1. Henry MS, Passmore AP, Todd S, et al. The development of effective biomarkers for Alzheimer's disease: a review. Int J Geriatr Psychiatry. 2013;28:331-340.
2. Grundke-Iqbal I, Iqbal K, Quinlan M, et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261:6084-6089.
3. Grundke-Iqbal I, Iqbal K, Tung YC, et al. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 1986;83:4913-4917.
4. Liu F, Zaidi T, Iqbal K, et al. Aberrant glycosylation modulates phosphorylation of tau by protein kinase and dephosphorylation of tau by protein phosphatase 2a and 5. Neuroscience. 2002;115:829-837.
5. Martin L, Latypova X, Wilson CM, et al. Tau protein kinases: Involvement in Alzheimer's disease. Ageing Res Rev. 2013;12:289-309.
6. Arriagada PV, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-639.
7. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17-24.
8. Duarte AI, Moreira PI, Oliveira CR. Insulin in central nervous system: more than just a peripheral hormone. J Aging Res. 2012;2012:384017.
9. Campbell RK. Clarifying the role of incretin-based therapies in the treatment of type 2 diabetes mellitus. Clin Ther. 2011;33:511-527.
10. Han W, Li C. Linking type 2 diabetes and Alzheimer's disease. Proc Natl Acad Sci U S A. 2010;107:6557-6558.
11. Kopf D, Frolich L. Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J Alzheimers Dis. 2009;16:677-685.
12. Park SA. A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol. 2011;7:10-18.
13. Craft S. Insulin resistance syndrome and Alzheimer's disease: age- and obesity-related effects on memory, amyloid, and inflammation. Neurobiol Aging. 2005;26(Suppl 1):65-69.
14. Duarte AI, Candeias E, Correia SC, et al. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. Biochim Biophys Acta. 1832;2013:527-541.
15. Moreira PI. Alzheimer's disease and diabetes: an integrative view of the role of mitochondria, oxidative stress, and insulin. J Alzheimers Dis. 2012;30(Suppl 2):S199-S215.
16. Hoyer S. Memory function and brain glucose metabolism. Pharmacopsychiatry. 2003;36(Suppl 1):S62-S67.
17. Piroli GG, Grillo CA, Charron MJ, et al. Biphasic effects of stress upon glut8 glucose transporter expression and trafficking in the diabetic rat hippocampus. Brain Res. 2004;1006:28-35.
18. Liu Y, Liu F, Grundke-Iqbal I, et al. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol. 2011;225:54-62.
19. Moloney AM, Griffin RJ, Timmons S, et al. Defects in igf-1 receptor, insulin receptor and irs-1/2 in Alzheimer's disease indicate possible resistance to igf-1 and insulin signalling. Neurobiol Aging. 2010;31:224-243.
20. Jolivalt CG, Lee CA, Beiswenger KK, et al. Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res. 2008;86:3265-3274.
21. Gao C, Holscher C, Liu Y, et al. Gsk3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease. Rev Neurosci. 2012;23:1-11.
22. Moller JB, Jusko WJ, Gao W, et al. Mechanism-based population modelling for assessment of l-cell function based on total glp-1 response following an oral glucose tolerance test. J Pharmacokinet Pharmacodyn. 2011;38:713-725.
23. Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.
24. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696-1705.
25. Holscher C. The incretin hormones glucagonlike peptide 1 and glucose-dependent insulinotropic polypeptide are neuroprotective in mouse models of Alzheimer's disease. Alzheimers Dement. 2014;10:S47-S54.
26. Yang Y, Zhang J, Ma D, et al. Subcutaneous administration of liraglutide ameliorates Alzheimer-associated tau hyperphosphorylation in rats with type 2 diabetes. J Alzheimers Dis. 2013;37:637-648.
27. Hamilton A, Holscher C. Receptors for the incretin glucagon-like peptide-1 are expressed on neurons in the central nervous system. Neuroreport. 2009;20:1161-1166.
28. Williams DL, Baskin DG, Schwartz MW. Evidence that intestinal glucagon-like peptide-1 plays a physiological role in satiety. Endocrinology. 2009;150:1680-1687.
29. Hui H, Tang YG, Zhu L, et al. Glucagon like peptide-1-directed human embryonic stem cells differentiation into insulin-producing cells via hedgehog, camp, and pi3k pathways. Pancreas. 2010;39:315-322.
30. During MJ, Cao L, Zuzga DS, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med. 2003;9:1173-1179.
31. Perry T, Haughey NJ, Mattson MP, et al. Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther. 2002;302:881-888.
32. McIntyre RS, Powell AM, Kaidanovich-Beilin O, et al. The neuroprotective effects of glp-1: possible treatments for cognitive deficits in individuals with mood disorders. Behav Brain Res. 2013;237:164-171.
33. Hunter K, Holscher C. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis. BMC Neurosci. 2012;13:33.
34. Hoistad M, Samskog J, Jacobsen KX, et al. Detection of beta-endorphin in the cerebrospinal fluid after intrastriatal microinjection into the rat brain. Brain Res. 2005;1041:167-180.
35. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419.
36. Liu Y, Liu F, Grundke-Iqbal I, et al. Brain glucose transporters, o-glcnacylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem. 2009;111:242-249.
37. Yang Y, Ma D, Wang Y, et al. Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes. J Alzheimers Dis. 2013;33:329-338.
38. Schuh AF, Rieder CM, Rizzi L, et al. Mechanisms of brain aging regulation by insulin: implications for neurodegeneration in late-onset Alzheimer's disease. ISRN Neurol. 2011;2011:306905.
39. Popkie AP, Zeidner LC, Albrecht AM, et al. Phosphatidylinositol 3-kinase (pi3k) signaling via glycogen synthase kinase-3 (gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem. 2010;285:41337-41347.
40. Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer's disease: a systematic review. Drugs. 2011;71:2031-2065.
41. Gong CX, Grundke-Iqbal I, Iqbal K. Targeting tau protein in Alzheimer's disease. Drugs Aging. 2010;27:351-365.
42. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012;9:35-66.
43. Abbas T, Faivre E, Holscher C. Impairment of synaptic plasticity and memory formation in glp-1 receptor ko mice: interaction between type 2 diabetes and Alzheimer's disease. Behav Brain Res. 2009;205:265-271.
44. Yang Y, Hu S, Zhang J, et al. Alzheimer-like hyperphosphorylation of tau in brains of rats with obesity and type 2 diabetes. Prog Biochem Biophys. 2006;33:458-464.